Sorafenib in Advanced Hepatocellular Carcinoma

Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean Frédéric Blanc, André Cosme de Oliveira, Armando Santoro, Jean‐Luc Raoul, Alejandro Forner, Myron Schwartz, Camillo Porta, Stefan Zeuzem, Luigi Bolondi, Tim F. Greten, Peter R. Galle, Jean François Seitz, Ivan Borbath, Dieter Häussinger, Tom Giannaris, Minghua Shan, M. Moscovici, D. Voliotis, Jordi Bruix

New England Journal of Medicine, 2008

Universitat de Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, University of Pisa, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Duisburg-Essen, Auckland City Hospital, Hôpital Saint-André, Universidade de São Paulo, Fondazione Humanitas per la Ricerca, EU Business School, Geneva, Centro de Investigación Biomédica en Red, Icahn School of Medicine at Mount Sinai, Policlinico San Matteo Fondazione, Istituti di Ricovero e Cura a Carattere Scientifico, Goethe University Frankfurt, University of Bologna, Medizinische Hochschule Hannover, Johannes Gutenberg University Mainz, Aix-Marseille Université, UCLouvain, Heinrich Heine University Düsseldorf, Bayer (United States)

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

12861

Citations

View on Google Scholar

Sorafenib in Advanced Hepatocellular Carcinoma

Abstract

Journal Details

Join JournalsHub

Welcome Back